Chapter 7. Genetics of Laminopathies

  1. Derek J. Chadwick Organizer,
  2. Jamie Goode
  1. Rabah Ben Yaou1,2,
  2. Antoine Muchir1,2,
  3. Takuro Arimura1,2,
  4. Catherine Massart1,2,
  5. Laurence Demay2,
  6. Pascale Richard2,
  7. Gisèle Bonne1,2,*

Published Online: 7 OCT 2008

DOI: 10.1002/0470093765.ch7

Nuclear Organization in Development and Disease: Novartis Foundation Symposium 264

Nuclear Organization in Development and Disease: Novartis Foundation Symposium 264

How to Cite

Yaou, R. B., Muchir, A., Arimura, T., Massart, C., Demay, L., Richard, P. and Bonne, G. (2008) Genetics of Laminopathies, in Nuclear Organization in Development and Disease: Novartis Foundation Symposium 264 (eds D. J. Chadwick and J. Goode), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470093765.ch7

Author Information

  1. 1

    Inserm U582, Institut de Myologie, Batiment Babinski, Groupe Hospitalier Pitié-Salpétrière, 47, Boulevard de l'Hôpital, Paris, France

  2. 2

    UF Cardiogénétique et Myogénétique, Groupe Hospitalier Pitié-Salpétrière, Assistance Publique-Hôpitaux de Paris, France

*Inserm U582, Institut de Myologie, Batiment Babinski, Groupe Hospitalier Pitié-Salpétrière, 47, Boulevard de l'Hôpital, Paris and UF Cardiogénétique et Myogénétique, Groupe Hospitalier Pitié-Salpé trière, Assistance Publique-Hôpitaux de Paris, France

Publication History

  1. Published Online: 7 OCT 2008
  2. Published Print: 14 JAN 2005

Book Series:

  1. Novartis Foundation Symposia

Book Series Editors:

  1. Novartis Foundation

ISBN Information

Print ISBN: 9780470093733

Online ISBN: 9780470093764

SEARCH

Keywords:

  • laminopathies;
  • encoding A-type lamins;
  • LMNA mutations;
  • Emery-Dreifuss muscular dystrophy (EDMD);
  • familial partial lipodystrophy of Dunningan (FPLD);
  • Mandibuloacral Dysplasia (MAD);
  • genetics of laminopathies;
  • X-linked and autosomal dominant (XL- and AD-EDMD)

Summary

Laminopathies are now recognized as a group of disorders due to mutations of the LMNA gene, which encodes A-type lamins. Primarily, mutations in LMNA have been associated to the autosomal forms of Emery-Dreifuss muscular dystrophy, a rare slowly progressive humero-peroneal muscular dystrophy accompanied by early contractures and dilated cardiomyopathy with conduction defects. LMNA mutations have been reported to be responsible for up to 10 distinct phenotypes that affect specifically either the skeletal and/or cardiac muscle, the adipose tissue, the peripheral nervous tissue, the bone tissue or more recently premature ageing. So far more than 180 different LMNA mutations have been identified in 903 individuals. The first studies of phenotype/genotype relationships revealed no clear relation between the phenotype and the type and/or the localization of the mutation, except perhaps for the globular tail domain of lamins A/C. Studies of the consequences of LMNA mutations in the skin cultured fibroblasts from the patients reveal abnormal nuclei in variable proportions, with dysmorphic nuclei exhibiting abnormal patterns of expression of B-type lamins and emerin. Finally, the development of KO and KI LMNA mice, will certainly give further insight into the pathophysiological mechanisms associated with LMNA mutations. For example, LmnaH222P/H222P mice harbour phenotypes reminiscent of Emery-Dreifuss muscular dystrophy.